Download Breast cancer subtypes PowerPoint Presentation

Iframe embed code :

<iframe src='https://www.slidesfinder.com/embedpresentation/ODk=' width='630' height='570' frameborder='0' marginwidth='0' marginheight='0' scrolling='no' allowfullscreen></iframe>

Presentation url :

Home / Health & Wellness / Health & Wellness Presentations / Breast cancer subtypes PowerPoint Presentation

Breast cancer subtypes PowerPoint Presentation

PowerPoint is the world's most popular presentation software which can let you create professional Breast cancer subtypes powerpoint presentation easily and in no time. This helps you give your presentation on Breast cancer subtypes in a conference, a school lecture, a business proposal, in a webinar and business and professional representations.

The uploader spent his/her valuable time to create this Breast cancer subtypes powerpoint presentation slides, to share his/her useful content with the world. This ppt presentation uploaded by slidesfinder in Health & Wellness ppt presentation category is available for free download,and can be used according to your industries like finance, marketing, education, health and many more.

About This Presentation

slidesfinder

Description : View and free download Breast cancer subtypes powerpoint presentation which is uploaded by honey an active user in belonging ppt presentation Health & Wellness category.

Tags : Breast cancer subtypes (Newman)

Published on : Dec 06, 2013
Views : 2067 | Downloads : 1

Download Now

Share on Social Media

Breast cancer subtypes Presentation Transcript

Slide 1 -

BREAST CANCER SUBTYPES:Association Between Aggressive Breast Cancer Subtypes and African Ancestry Lisa A. Newman, M.D., M.P.H., F.A.C.S. Professor of Surgery Director, Breast Care Center University of Michigan Ann Arbor, MI

Slide 2 -

Goals of Breast Cancer Treatment Local/Regional Treatment: to control/eliminate disease in breast and regional lymph nodes Surgery Radiation Therapy Systemic Treatment: to control/eliminate disease in distant organs Chemotherapy Endocrine/Hormonal Therapy Other Targeted Therapy (e.g. Herceptin)

Slide 3 -

Breast Cancer Treatment All breast cancer patients are at risk for having metastatic disease in distant organs (liver, lungs, bones, etc) Early-stage breast cancer pts more likely to have microscopic metastases (microscopic, invisible disease; micrometastases) Highest risk in pts with bulky, locally-advanced, node-positive breast cancer Systemic therapy can control distant organ metastases Staging information (TNM) provides clues regarding risk of micrometastatic disease Systemic therapy most likely to be successful if: Micrometastatic burden is low (early-stage disease) Systemic therapy is TARGETED to individual tumor biology

Slide 4 -

Systemic Therapy for Breast Cancer Chemotherapy “generic” systemic therapy: kills any rapidly-dividing cells in the body Endocrine/Hormonally-active therapy Tamoxifen; Aromatase Inhibitors Target ER-positive and/or PR-positive breast cancer cells Herceptin/Trastuzamab Targets HER2/neu-positive breast cancer

Slide 5 -

Systemic Therapy for Breast Cancer Appropriate systemic therapy can improve breast cancer survival by 20-30% Preoperative (neoadjuvant) systemic therapy can convert locally-advanced/inoperable breast cancer to resectable disease can improve ease of surgery for any bulky cancer Success of systemic therapy: COMPLETELY dependent upon having information regarding tumor markers (ER, PR, and HER2/neu)

Slide 6 -

What are breast cancer subtypes? What is the relationship between breast cancer subtypes and systemic therapy for breast cancer?

Slide 7 -

ppt slide no 7 content not found

Slide 8 -

“Basal-like” breast cancer Gene expression profile Most tightly clustered subgroup in gene expression arrays CK 5/6 and 17 expression P53 mutations EGFR overexpression Mostly “triple negative” Morphology High grade Mainly ductal or medullary High mitotic count Scant stroma Central necrosis Pushing border Lymphocytic infiltrate Apoptotic figures BRCA1 connection Gene expression similar Morphology similar

Slide 9 -

Sorlie et al. PNAS 2003 ER++, PR++, G1,2 HER2 ISH pos “triple neg,” CK5/6+

Slide 10 -

Triple-Positive Breast Cancer Triple-Negative Breast Cancer H&E ER-Neg PR-Neg HER2/neu-Neg ER-Pos PR-Pos HER2/neu-Pos H&E

Slide 11 -

Relevance of “Triple-Negative” Breast Cancer Tumors that do not express the ER, PR, and HER2/neu markers are more likely to be basal-subtype tumors Inherently aggressive biologic behavior Triple-negativity used as a surrogate for basal subtype Tumors that do not express the ER, PR, and HER2/neu markers have fewer systemic therapy options Endocrine/hormonal therapy will be ineffective Herceptin therapy will be ineffective Chemotherapy IS effective

Slide 12 -

BREAST CANCER SUBTYPES:Association Between Aggressive Breast Cancer Subtypes and African Ancestry Association initially suggested by observations of disparities in the breast cancer burden of African Americans and White/European Americans Most available data therefore based upon studies of African American breast cancer pts and ER status

Slide 13 -

BREAST CANCER IN AFRICAN AMERICANS Overall lower lifetime incidence Higher mortality More advanced stage distribution Younger age distribution Increased frequency of adverse prognostic tumor features Higher incidence of male breast cancer

Slide 14 -

NCDB: Frequency of ER-Negative Tumors by Age, Stage, and Income 1998; N=170K; approximately 10% AA

Slide 15 -

Hance, K. W. et al. J. Natl. Cancer Inst. 2005 97:966-975 Frequency of ER-Neg Breast Cancer NOT Explained by Stage Distribution: Age-specific incidence rates by ER status and race

Slide 16 -

Frequency of ER-Negative Breast Cancer NOT Explained by Poverty: International Data on SES and ER Status Glasgow, Scotland (Thomson et al, J Epi & Comm Health, 2001) 35% ER-negative for affluent women compared to 52% ER-negative for impoverished women ER status missing for one-third of cases Glasgow, Scotland (Carnon et al, BMJ 1994) 51% ER-negative for affluent women compared to 52% ER-negative for impoverished women Sweden National Health Care System (Halmin et al Acta Oncologica, 2008) 37% ER-negative; no differences by SES London, England (Bowen et al Br J Cancer, 2008) 34% ER-neg for British Black women compared to 25% ER-neg for British White women; results unchanged by SES stratification

Slide 17 -

ppt slide no 17 content not found

Slide 18 -

High-Risk Breast Cancer and African Ancestry Parallels between hereditary breast cancer and breast cancer in women with African ancestry younger age distribution increased prevalence of ER-neg, aneuploid tumors higher risk of male breast cancer Is African ancestry associated with a heritable marker for high-risk breast cancer subtypes? Unique opportunity to gain insights regarding etiology of breast cancer disparities and the pathogenesis of triple-negative breast cancer

Slide 19 -

Breast Cancer in African American, Sub-Saharan African, and White American Women

Slide 20 -

Research Project: KATH-UM International Breast Cancer Registry To systematically evaluate African ancestry as a risk factor for ER/triple-negative, early onset breast cancer Multicenter/international study African Americans (UM; Henry Ford Hospital) White Americans (UM; Henry Ford Hospital) Ghanaians (Komfo Anoyke Teaching Hospital) Document correlation between quantified extent of ancestry (via genotyping) and risk for ER-negative/triple-negative breast cancer (via tumor studies)

Slide 21 -

Preliminary Results(in press, Cancer)

Slide 22 -

ppt slide no 22 content not found

Slide 23 -

Patterns Among Locally-Advanced, Grade 3 Tumors

Slide 24 -

Other African Datasets Huo et al (Olopade) JCO 2009 378 breast cancers from Nigeria and Senegal 1996-2007 Mean age 45 yrs 76% ER-negative 73% triple-negative Bird et al Ann Surg Onc 2008 120 breast cancers from Kenya 2001-2007 Median age 47 yrs 76% ER-negative 44% triple-negative (subset of 34 tumors)

Slide 25 -

Breast Cancer Stem Cells

Slide 26 -

ALDH1 as a Breast Cancer Stem Cell Marker Article ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical Outcome Christophe Ginestier, Max S. Wicha and Gabriela Dontu, et al University of Michigan, Ann Arbor MI Laboratoire d'Oncologie Moléculaire, Centre de Recherche en Cancérologie de Marseille, France November 2007, Pages 555-567

Slide 27 -

ALDH-1 Staining by Race/Ethnicity Ghanaian Cases: 20/23 (87%) University of Michigan White American cases: 24/146 (19%) French/European cases: 102/345 (30%) White American/European ER-negative cases 39/80 (50%)

Slide 28 -

ALDH1/Breast CA Stem Cell Marker: Ghanaian Breast Cancer Case

Slide 29 -

THANK YOU!!!!!

Frequently Asked Questions

> About SlidesFinder?

Slidesfinder is a website that allows users to upload and share their PowerPoint presentations online. It provides a platform for individuals and businesses to share their ideas and knowledge through presentations, and for others to view and download these presentations for educational or professional purposes.
Slidesfinder offers a wide range of presentation topics and categories, including business, education, science, technology, health, and more. Users can also search for presentations using keywords, tags, or by category. The website provides tools to create professional presentations with rich media, animations, and graphics.

One of the key features of Slidesfinder is its user-friendly interface, which allows users to easily upload, view, and share presentations. Users can also embed their presentations in their websites or blogs using the website's embed code feature.
Slidesfinder also offers premium services, such as the ability to create private presentations and to download presentations in high-quality formats. However, the basic features of Slidesfinder are free to use, making it accessible to anyone who wants to share their ideas and knowledge through presentations.

> How do I register with SlidesFinder?

Go to registration page (you can see signup link on top of website page) https://www.slidesfinder.com/signup . If you have facebook/gmail account them just click on SIGN IN WITH FACEBOOK OR SIGN IN WITH GOOGLE button, by this you will be a registered member of slidesfinder without filling any form, required detail automatically will be fatch from your account. If you do not a Facebook account, then click on "Signup". Fill all required fields and you will be a registered member of slidesfinder.

> Is slidesfinder account confirmation is mandatory?

Yes it is mandetory to active your account to login.

> Do I need to signup/login on SlidesFinder before uploading a PowerPoint presentation?

Yes, you need to login with your account before uploading presentation. Your username will be displayed on your uploaded presentation. Your registered email id is needed for sending your stats of uploaded presentation.

Slidesfinder is a sharing website for PowerPoint presentations search and share. Find your interest in the form of powerpoint presentations on slidesfinder and save your valuable time . On Slidesfinder you get presentations from our huge library of professional ppt presentations. We believe in making your search INFORMATIVE and FUN. Find your best ppt presentation from a pool of PowerPoint presentations stacked under important industry categories like business & management, heath & Wellness,eduction & training etc. We provide unique informative PowerPoint presentation for marketers, presenters and educationists. These professional PowerPoint presentations are uploaded by professionals from across numerous industry segments.These ppt presentations are available for FREE download.

Not just finding your interest, but facilitate you broadcast your interest. We have created this platform for easy sharing of PowerPoint presentations, ensuring that these presentations get maximum exposure. Create your slidesfinder account and upload PowerPoint presentations for free, share on social media platforms and BUILD YOUR CROWD WITH PRESENTATION !!

The Great Buddha says, "Share your knowledge.It’s a way to achieve immortality"! So, start sharing knowledge and we are here to make that immortal !!

Re-productivity of content are not allowed. Without prior written permission from author, commercial use of any content is illegal.